Physician profile
Sapho Doan
NPI 1427062041
$2,906.53
in general payments reported to CMS, 2019-2025
21 companies · $932 in 2025
The $932 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $295 · 2021: $168 · 2022: $394 · 2023: $273 · 2024: $715 · 2025: $932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,768 · Entertainment: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,767.81 |
| Entertainment | $151.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $471.98 | 2022-2025 | Infuse, Xiidra, Miebo |
| Tarsus Pharmaceuticals, INC. | $462.22 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $367.87 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $316.81 | 2020-2025 | Precision 1, Precision7, Dailies Total1 |
| Glaukos Corporation | $174.66 | 2025 | Photrexa Viscous and Photrexa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $160.34 | 2019-2021 | |
| Optos, INC. | $151.82 | 2024-2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Sun Pharmaceutical Industries INC. | $128.27 | 2019-2025 | |
| Coopervision INC. | $116.01 | 2021-2025 | Myday Contact Lens |
| Abbvie INC. | $99.42 | 2022-2024 | |
| Biotissue Holdings INC. | $97.75 | 2025 | |
| Kala Pharmaceuticals, INC. | $63.77 | 2021 | |
| Oasis Medical, INC. | $62.27 | 2019-2024 | Oasis Tears |
| Carl Zeiss Meditec Ag | $58.20 | 2020 | |
| Novartis Pharmaceuticals Corporation | $40.44 | 2020-2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $33.19 | 2025 | Oxervate |
| Spark Therapeutics, INC. | $27.83 | 2022 | |
| Harrow Eye, LLC | $23.00 | 2025 | Vevye |
| Plexus Optix, INC. | $18.03 | 2021 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Oyster Point Pharma, INC. | $15.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sapho Doan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.